Rachel Scheckter
Overview
Explore the profile of Rachel Scheckter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
599
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Browne E, Brown E, Palanee-Phillips T, Reddy K, Naidoo L, Jeenarain N, et al.
J Acquir Immune Defic Syndr
. 2022 Mar;
90(4):418-424.
PMID: 35344520
Background: Persistent use of HIV prevention methods can be a challenge, particularly for some younger women. The long-acting, discreet, woman-centric dapivirine vaginal ring offers promise as a prevention method with...
12.
Stoner M, Browne E, Gundacker H, Hawley I, Chen B, Hoesley C, et al.
PLoS One
. 2022 Feb;
17(2):e0263664.
PMID: 35192655
Given challenges with adherence to existing HIV prevention products, the development of an extended duration vaginal ring could improve adherence while reducing patient and provider burden. Additionally, women have other...
13.
Hawley I, Song M, Scheckter R, McClure T, Piper J, Chen B, et al.
AIDS Res Hum Retroviruses
. 2021 Dec;
38(4):313-326.
PMID: 34969254
Vaginal rings address a critical need for an independently initiated, long-acting HIV prevention method, but their design must be acceptable to promote uptake and adherence. Human-centered design (HCD) may help...
14.
Garcia M, Luecke E, Mayo A, Scheckter R, Ndase P, Kiweewa F, et al.
BMC Public Health
. 2021 Nov;
21(1):2041.
PMID: 34749675
Background: Low adherence to investigational products can negatively impact study outcomes, limiting the ability to demonstrate efficacy. To continue advancing potential new HIV prevention technologies, efforts are needed to improve...
15.
Gichane M, Katz A, Ngure K, Scheckter R, Woeber K, Reddy K, et al.
AIDS Behav
. 2021 May;
25(12):3847-3857.
PMID: 34009480
The monthly dapivirine vaginal ring has proven efficacious in reducing HIV incidence in two Phase 3 clinical trials. When considering the potential future availability of the ring to the public,...
16.
Baeten J, Palanee-Phillips T, Mgodi N, Mayo A, Szydlo D, Ramjee G, et al.
Lancet HIV
. 2021 Feb;
8(2):e87-e95.
PMID: 33539762
Background: Two phase 3 clinical trials showed that use of a monthly vaginal ring containing 25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by approximately 30%...
17.
van der Straten A, Browne E, Shapley-Quinn M, Brown E, Reddy K, Scheckter R, et al.
J Acquir Immune Defic Syndr
. 2019 Mar;
81(3):304-310.
PMID: 30844995
Background: In MTN-020/ASPIRE, a dapivirine vaginal ring effectiveness trial in sub-Saharan Africa, we assessed whether worries about ring use changed over time and were associated with adherence. Methods: Participants (N...
18.
Noguchi L, Hoesley C, Kelly C, Scheckter R, Bunge K, Nel A, et al.
Antimicrob Agents Chemother
. 2019 Jan;
63(3).
PMID: 30602513
Breastfeeding (BF) women are an important population for biomedical HIV prevention strategies, but they are rarely included in trials. The 25-mg dapivirine vaginal ring (VR) reduced women's risk of sexually...
19.
Makanani B, Balkus J, Jiao Y, Noguchi L, Palanee-Phillips T, Mbilizi Y, et al.
J Acquir Immune Defic Syndr
. 2018 Nov;
79(5):566-572.
PMID: 30383589
Background: Monthly use of the dapivirine vaginal ring has been shown to be safe and effective for HIV-1 prevention in nonpregnant reproductive-aged women. The impact of dapivirine on pregnancy outcomes...
20.
Mhlanga F, Noguchi L, Balkus J, Kabwigu S, Scheckter R, Piper J, et al.
HIV Clin Trials
. 2017 Dec;
19(1):8-14.
PMID: 29268654
Background: Safety data on pregnancy and fetal outcomes among women in HIV prevention trials are urgently needed to inform use of effective antiretroviral agents for HIV prevention. We describe an...